The significance of elevated tumor markers among patients with idiopathic pulmonary fibrosis before and after lung transplantation

Chest

Volumn 141, Issue 4, 2012, Pages 1047-1054

  Rusanov, Victoria ^a   Kramer, Mordechai R ^a   Raviv, Yael ^a   Medalion, Benjamin ^a   Guber, Alexander ^b,c   Shitrit, David ^b,c  

^a RABIN MEDICAL CENTER   (Israel)

^b MEIR MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CARBOHYDRATE ANTIGEN; TUMOR MARKER;

ADULT; ARTICLE; CARDIOPULMONARY EXERCISE TEST; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOPPLER ECHOCARDIOGRAPHY; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; HUMAN; LUNG FUNCTION TEST; LUNG TRANSPLANTATION; MALE; PATIENT ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL RATE;

EID: 84859502383     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.11-0284     Document Type: Article

References (31)

1. American Thoracic Society. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000;161(2 pt 1):646-664.
2. Agusti AG, Roca J, Rodriguez-Roisin R, Xaubet A, Agusti-Vidal A. Different patterns of gas exchange response to exercise in asbestosis and idiopathic pulmonary fibrosis. Eur Respir J. 1988; 1(6):510-516.
3. O'Donnell DE. Physiology of interstitial lung disease. In: Schwarz M, King T Jr, eds. Interstitial Lung Disease. Hamilton, ON, Canada: BC Decker;1998:51-70.
4. Hansen JE, Wasserman K. Pathophysiology of activity limitation in patients with interstitial lung disease. Chest. 1996; 109(6):1566-1576. (Pubitemid 26193386)
5. King TE Jr, Tooze JA, Schwarz MI, Brown KR, Cherniack RM. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med. 2001; 164(7):1171-1181. (Pubitemid 33052246)
6. Martinez FJ, Safrin S, Weycker D, et alIPF Study Group. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med. 2005;142(12 pt 1):963-967.
7. Hosenpud JD, Bennett LE, Keck BM, Edwards EB, Novick RJ. Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease. Lancet. 1998; 351(9095):24-27. (Pubitemid 28020162)
8. Prasse A, Probst C, Bargagli E, et al. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009;179(8): 717-723.
9. Miller MR, Hankinson J, Brusasco V, et alATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005; 26(2):319-338. (Pubitemid 41079078)
10. Wanger J, Clausen JL, Coates A, et alAmerican Thoracic Society;European Respiratory Society. Standardisation of the measurement of lung volumes. Eur Respir J. 2005;26(3): 511-522. (Pubitemid 41264217)
11. Macintyre N, Crapo RO, Viegi G, et alAmerican Thoracic Society;European Respiratory Society. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J. 2005;26(4):720-735. (Pubitemid 41448672)
12. American Thoracic Society;American College of Chest Physicians. ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2003;167(2): 211-277.
13. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111-117.
14. Carmosino MJ, Friesen RH, Doran A, Ivy DD. Perioperative complications in children with pulmonary hypertension undergoing noncardiac surgery or cardiac catheterization. Anesth Analg. 2007;104(3):521-527.
15. Lai HC, Lai HC, Wang KY, Lee WL, Ting CT, Liu TJ. Severe pulmonary hypertension complicates postoperative outcome of non-cardiac surgery. Br J Anaesth. 2007;99(2): 184-190.
16. Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med. 2003; 168(5):531-537. (Pubitemid 37088594)
17. Flaherty KR, Mumford JA, Murray S, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003;168(5):543-548. (Pubitemid 37088596)
18. Erbes R, Schaberg T, Loddenkemper R. Lung function tests in patients with idiopathic pulmonary fibrosis. Are they helpful for predicting outcome? Chest. 1997;111(1): 51-57.
19. Noble PW, Morris DG. Time will tell: predicting survival in idiopathic interstitial pneumonia [editorial]. Am J Respir Crit Care Med. 2003;168(5):510-511. (Pubitemid 37088590)
20. Moloney ED, Clayton N, Mukherjee DK, Gallagher CG, Egan JJ. The shuttle walk exercise test in idiopathic pulmonary fibrosis. Respir Med. 2003;97(6):682-687. (Pubitemid 36675672)
21. American Association for Respiratory Care. AARC clinical practice guideline: exercise testing for evaluation of hypoxemia and/or desaturation. Respir Care. 2001; 46(4):514- 522.
22. Kadikar A, Maurer J, Kesten S. The six-minute walk test: a guide to assessment for lung transplantation. J Heart Lung Transplant. 1997;16(3):313-319. (Pubitemid 27138296)
23. Thomeer M, Grutters JC, Wuyts WA, Willems S, Demedts MG. Clinical use of biomarkers of survival in pulmonary fibro sis. Respir Res. 2010;11:89.
24. Shiota Y, Furuya K, Kitade M, Ueda N. CEA and CA19-9 in BALF from patients with idiopathic interstitial pneumonia [in Japanese]. Nihon Kyobu Shikkan Gakkai Zasshi. 1989; 27(8):887-893. (Pubitemid 19240788)
25. Obayashi Y, Fujita J, Nishiyama T, et al. Role of carbohydrate antigens sialyl Lewis (a) (CA19-9) in bronchoalveolar lavage in patients with pulmonary fibrosis. Respiration. 2000; 67(2):146-152. (Pubitemid 30193086)
26. Matsuoka Y, Endo K, Kawamura Y, et al. Normal bronchial mucus contains high levels of cancer-associated antigens, CA125, CA19-9, and carcinoembryonic antigen. Cancer. 1990; 65(3):506-510. (Pubitemid 20058368)
27. Kruit A, Gerritsen WB, Pot N, Grutters JC, van den Bosch JM, Ruven HJ. CA 15-3 as an alternative marker for KL-6 in fibrotic lung diseases. Sarcoidosis Vasc Diffuse Lung Dis. 2010; 27(2):138-146.
28. Kim HR, Lee CH, Kim YW, Han SK, Shim YS, Yim JJ. Increased CA 19-9 level in patients without malignant disease. Clin Chem Lab Med. 2009;47(6):750-754.
29. Wong RC, Brown S, Clarke BE, Klingberg S, Zimmerman PV. Transient elevation of the tumor markers CA 15-3 and CASA as markers of interstitial lung disease rather than underlying malignancy in dermatomyositis sine myositis. J Clin Rheumatol. 2002;8(4):204-207. (Pubitemid 34879359)
30. Vergote IB, Onsrud M, Børmer OP, Sert BM, Moen M. CA125 in peritoneal fluid of ovarian cancer patients. Gynecol Oncol. 1992;44(2):161-165.
31. Gullu I, Yalcin S, Tekuzman G. Tumor markers in effusions: a comparative study of tumor marker levels in sera and effusions. In: Travis CC, ed. Use of Biomarkers in Assessing Health and Environmental Impacts of Chemical Pollutants. New York, NY: Plenum Press;1993:265-272